1.47
price down icon5.16%   -0.08
 
loading
Celularity Inc stock is traded at $1.47, with a volume of 14,074. It is down -5.16% in the last 24 hours and down -44.61% over the past month. Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
See More
Previous Close:
$1.55
Open:
$1.5
24h Volume:
14,074
Relative Volume:
0.60
Market Cap:
$34.08M
Revenue:
$14.79M
Net Income/Loss:
$-181.41M
P/E Ratio:
-3.00
EPS:
-0.49
Net Cash Flow:
$-68.18M
1W Performance:
-13.02%
1M Performance:
-44.61%
6M Performance:
-55.32%
1Y Performance:
-37.18%
1-Day Range:
Value
$1.45
$1.50
1-Week Range:
Value
$1.30
$1.71
52-Week Range:
Value
$1.30
$7.97

Celularity Inc Stock (CELU) Company Profile

Name
Name
Celularity Inc
Name
Phone
(908) 768-2170
Name
Address
170 PARK AVE, FLORHAM PARK
Name
Employee
120
Name
Twitter
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
CELU's Discussions on Twitter

Celularity Inc Stock (CELU) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-30-23 Downgrade Morgan Stanley Equal-Weight → Underweight
Dec-22-22 Downgrade Oppenheimer Outperform → Perform
Jun-22-22 Initiated H.C. Wainwright Buy
Apr-06-22 Downgrade Truist Buy → Hold
Jan-28-22 Initiated Oppenheimer Outperform
Nov-24-21 Initiated Morgan Stanley Equal-Weight
View All

Celularity Inc Stock (CELU) Latest News

pulisher
Oct 31, 2024

CELU stock touches 52-week low at $1.55 amid market fluctuations - Investing.com India

Oct 31, 2024
pulisher
Oct 30, 2024

CELU stock touches 52-week low at $1.55 amid market fluctuations By Investing.com - Investing.com South Africa

Oct 30, 2024
pulisher
Oct 26, 2024

Celularity reports over $24 million in biomaterial revenue By Investing.com - Investing.com Australia

Oct 26, 2024
pulisher
Oct 26, 2024

Celularity Inc. Announces Anticipated Revenues for Second and Third Quarters - Defense World

Oct 26, 2024
pulisher
Oct 25, 2024

Celularity reports over $24 million in biomaterial revenue - Investing.com India

Oct 25, 2024
pulisher
Oct 23, 2024

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel - The Manila Times

Oct 23, 2024
pulisher
Oct 23, 2024

Celularity reports progress on Nasdaq compliance and product sales - Investing.com

Oct 23, 2024
pulisher
Oct 22, 2024

Celularity reports progress on Nasdaq compliance and product sales By Investing.com - Investing.com Australia

Oct 22, 2024
pulisher
Oct 22, 2024

Celularity Provides Corporate Update - citybiz

Oct 22, 2024
pulisher
Oct 22, 2024

CELUWCelularity Inc. Warrant Latest Stock News & Market Updates - StockTitan

Oct 22, 2024
pulisher
Oct 21, 2024

Celularity faces Nasdaq delisting over reporting delays - Investing.com

Oct 21, 2024
pulisher
Oct 21, 2024

Celularity faces Nasdaq delisting over reporting delays By Investing.com - Investing.com UK

Oct 21, 2024
pulisher
Oct 18, 2024

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal - ForexTV.com

Oct 18, 2024
pulisher
Oct 17, 2024

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc. - The Manila Times

Oct 17, 2024
pulisher
Oct 16, 2024

Celularity expands biomaterials range with Rebound acquisition - Investing.com India

Oct 16, 2024
pulisher
Oct 16, 2024

Celularity Inc SEC 10-Q Report - TradingView

Oct 16, 2024
pulisher
Oct 03, 2024

Celularity (NASDAQ:CELU) Stock Price Down 8.8%Should You Sell? - MarketBeat

Oct 03, 2024
pulisher
Sep 19, 2024

Amniotic Membrane Market to Grow by USD 2.7 Billion (2024-2028) with AI Impact Boosting Trends in Ophthalmic Surgery UseTechnavio Report - The Malaysian Reserve

Sep 19, 2024
pulisher
Sep 18, 2024

BTIG maintains Buy rating on Cullinan Oncology stock - Investing.com

Sep 18, 2024
pulisher
Sep 18, 2024

Cullinan Oncology maintains Buy rating from H.C. Wainwright with steady price target - Investing.com India

Sep 18, 2024
pulisher
Sep 18, 2024

Trend Tracker for (CLS) - Stock Traders Daily

Sep 18, 2024
pulisher
Sep 18, 2024

Cullinan Therapeutics (NASDAQ:CGEM) Earns Outperform Rating from Wedbush - MarketBeat

Sep 18, 2024
pulisher
Sep 18, 2024

Caesars Entertainment Inc (CZR) stock: A year of ups and downs - US Post News

Sep 18, 2024
pulisher
Sep 18, 2024

In the Green: Cerus Corp. (CERS) Closes at 1.97, Up/Down -4.37 from Previous Day - The Dwinnex

Sep 18, 2024
pulisher
Sep 18, 2024

Creo Medical to get £25m boost from majority sale of its European business - Business Live

Sep 18, 2024
pulisher
Sep 18, 2024

Medical device company to sell stake of subsidiary to Chinese manufacturerequity value of €72m - Insider Media

Sep 18, 2024
pulisher
Sep 18, 2024

Objective long/short (CGEM) Report - Stock Traders Daily

Sep 18, 2024
pulisher
Sep 18, 2024

CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA - Yahoo Finance

Sep 18, 2024
pulisher
Sep 18, 2024

Cullinan Therapeutics Inc (CGEM)’s stock price in review: A technical analysis - US Post News

Sep 18, 2024
pulisher
Sep 18, 2024

(CELC) Technical Pivots with Risk Controls - Stock Traders Daily

Sep 18, 2024
pulisher
Sep 18, 2024

Creo Medical Partners with Micro-Tech for Strategic Growth - TipRanks

Sep 18, 2024
pulisher
Sep 18, 2024

E Fund Management Co. Ltd. Purchases New Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat

Sep 18, 2024
pulisher
Sep 18, 2024

State of New Jersey Common Pension Fund D Has $3.31 Million Stock Holdings in Caesars Entertainment, Inc. (NASDAQ:CZR) - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Cellectis (NASDAQ:CLLS) Coverage Initiated at StockNews.com - MarketBeat

Sep 18, 2024
pulisher
Sep 18, 2024

Cullinan Therapeutics commences Phase 1 trial for lupus treatment By Investing.com - Investing.com Canada

Sep 18, 2024
pulisher
Sep 17, 2024

Celcuity Inc. (NASDAQ:CELC) Short Interest Update - MarketBeat

Sep 17, 2024
pulisher
Sep 17, 2024

Capricor shares gain as Oppenheimer raises price target to $15 - Investing.com

Sep 17, 2024
pulisher
Sep 17, 2024

Cullinan Therapeutics (NASDAQ:CGEM) Shares Up 5.5% - MarketBeat

Sep 17, 2024
pulisher
Sep 17, 2024

Certara (NASDAQ:CERT) Shares Up 5% - MarketBeat

Sep 17, 2024
pulisher
Sep 17, 2024

How Is The Market Feeling About Celestica? - Benzinga

Sep 17, 2024
pulisher
Sep 17, 2024

Should You Increase Your Holdings in Certara (CERT)? - Insider Monkey

Sep 17, 2024
pulisher
Sep 17, 2024

Centerra Gold shares target raised on molybdenum unit outlook - Investing.com India

Sep 17, 2024
pulisher
Sep 17, 2024

Views of Wall Street’s Leading Experts on Centerra Gold Inc. - SETE News

Sep 17, 2024
pulisher
Sep 17, 2024

Centuri Holdings, Inc. (NYSE:CTRI) Short Interest Update - Defense World

Sep 17, 2024
pulisher
Sep 17, 2024

Caesars Entertainment Inc’s latest rating changes from various analysts - Knox Daily

Sep 17, 2024
pulisher
Sep 17, 2024

Celadon Pharmaceuticals Expands Share Capital - TipRanks

Sep 17, 2024
pulisher
Sep 16, 2024

Certara (NASDAQ:CERT) Sees Strong Trading Volume - MarketBeat

Sep 16, 2024
pulisher
Sep 16, 2024

Is Caesars Entertainment, Inc. (NASDAQ:CZR) the Best Las Vegas Stock To Buy Now? - Yahoo Finance

Sep 16, 2024
pulisher
Sep 16, 2024

Analyzing Ratios: Cullinan Therapeutics Inc (CGEM)’s Financial Story Unveiled - The Dwinnex

Sep 16, 2024
pulisher
Sep 16, 2024

Cullinan Oncology's stock gets buy rating after trial data - Investing.com

Sep 16, 2024
pulisher
Sep 16, 2024

Does Cerus Corp. (CERS) offer a good opportunity for investors? - SETE News

Sep 16, 2024

Celularity Inc Stock (CELU) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.30
price up icon 1.75%
$75.59
price down icon 0.20%
$374.10
price down icon 0.29%
$52.67
price down icon 0.85%
$207.67
price up icon 0.20%
$108.59
price up icon 0.02%
Cap:     |  Volume (24h):